Filing Flows › bioAffinity Technologies (BIAF) › Q1 2025
bioAffinity Technologies (BIAF) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
bioAffinity Technologies (BIAF) reported revenue of $1.9M for the first quarter 2025 (Q1 2025), -23% from a year earlier and -16% from the quarter before. Operating margin was -141.7%, net loss $2.7M (143.5% of revenue).
bioAffinity Technologies, Q1 2025: revenue $1.9M (-23% year over year), operating margin -141.7%, net loss $2.7M, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | -16% | -23% |
| Operating profit | −$2.6M | — | — |
| Net earnings | −$2.7M | — | — |
| Operating cash flow | −$1.6M | — | — |
What changed
Revenue was $1.9M in Q1 2025, down 23% year over year and down 16% from the previous quarter. Health Care, Patient Service was the largest line at 85% of revenue. Health Care, Patient Service lost $579K year over year (down 27%), 105% of the total change.
Operating costs exceeded revenue by $2.6M, an operating margin of -141.7%. Total costs grew 3% against a revenue fall of 23%. The fastest-growing cost line was SG&A (+12%). The quarter ended with a net loss of $2.7M, narrower than the previous quarter's $3.0M loss.
Operating cash flow was −$1.6M. Non-cash charges added back $155K of depreciation and amortization and $327K of share-based compensation. Working capital and other items added $537K. Capital expenditures of $51K exceeded it, leaving free cash flow of −$1.7M.
Questions
What was bioAffinity Technologies' revenue in the first quarter 2025?
bioAffinity Technologies (BIAF) reported revenue of $1.9M for the first quarter 2025 (Q1 2025), -23% from a year earlier and -16% from the quarter before.
Was bioAffinity Technologies profitable in the first quarter 2025?
Operating loss was $2.6M (-141.7% of revenue) and net loss $2.7M.